Loading
Preparing stock search
Loading the search box, recent screening context, and the surrounding editorial guidance.
Help keep us running — this site is free to use and we cover the running costs ourselves. We're open to sponsors and advertising to keep it online. Get in touch.
Heads up — we're updating the site with more recent financial data over the coming days. Thanks for being patient with us.
Loading
Loading the search box, recent screening context, and the surrounding editorial guidance.
Company report
Review the methodology status, formula details, and supporting context for ATAI.
Methodology
AAOIFI
DJIM
S&P Shariah
Company
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.
Debt ratio
Formula
Total Interest-Bearing Debt / Market Capitalization (or Avg for AAOIFI/DJIM)
Thresholds
Cash ratio
Formula
(Cash + Interest-Bearing Securities) / Market Capitalization
Thresholds
Analysis
Haram revenue
Formula
Impermissible Revenue / Total Revenue
Thresholds
Methodology